The recent price decline of 17% in MBX Biosciences, Inc.'s (NASDAQ:MBX) stock may have disappointed insiders who bought US$534.5k worth of shares at an average price of US$10.69 in the past 12 months.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...